The University of Southampton
University of Southampton Institutional Repository

Management of idiopathic pulmonary fibrosis

Management of idiopathic pulmonary fibrosis
Management of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls. Pirfenidone has been approved for the treatment of IPF in many countries, but is not recommended as a first-choice therapy by current guidelines because of the lack of a definite efficacy. Randomized controlled trials represent a valid choice for patients with IPF, and their completion is important in improving both survival and quality of life.
0272-5231
85-94
Cerri, Stefania
7ea9bc28-eaf2-46ce-8433-b9e732484b5f
Spagnolo, Paolo
402ffcfa-f566-48e8-986a-5b0b2930d4ae
Luppi, Fabrizio
63b544e0-fbe9-490a-8bcd-e5452a46a234
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Cerri, Stefania
7ea9bc28-eaf2-46ce-8433-b9e732484b5f
Spagnolo, Paolo
402ffcfa-f566-48e8-986a-5b0b2930d4ae
Luppi, Fabrizio
63b544e0-fbe9-490a-8bcd-e5452a46a234
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26

Cerri, Stefania, Spagnolo, Paolo, Luppi, Fabrizio and Richeldi, Luca (2012) Management of idiopathic pulmonary fibrosis. Clinics in Chest Medicine, 33 (1), 85-94. (doi:10.1016/j.ccm.2011.11.005). (PMID:22365248)

Record type: Article

Abstract

Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls. Pirfenidone has been approved for the treatment of IPF in many countries, but is not recommended as a first-choice therapy by current guidelines because of the lack of a definite efficacy. Randomized controlled trials represent a valid choice for patients with IPF, and their completion is important in improving both survival and quality of life.

Full text not available from this repository.

More information

Published date: March 2012
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 369083
URI: https://eprints.soton.ac.uk/id/eprint/369083
ISSN: 0272-5231
PURE UUID: 7d409d2e-2030-4be8-8228-f3581ab006fa

Catalogue record

Date deposited: 24 Sep 2014 12:04
Last modified: 18 Jul 2017 01:40

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×